The progression of Ontuxizumab, initially designated as MORAb-004, illustrates a notable undertaking in antibody therapy. Scientists at the company started work on this engineered monoclonal protein targeting CD3, https://mayagice307009.blogdigy.com/ontuxizumab-morab-004-a-deep-dive-into-its-development-65369716